ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

Venetoclax plus obinutuzumab has proved to be effective as frontline therapy in patients with Chronic Lymphocytic Leukemia (CLL). In this MEDtalk, Matthew S. Davids presents a trial-in-progress, investigating retreatment responses with venetoclax plus obinutuzumab in patients with relapsed CLL. Matthew is hoping for the results to support a future retreatment regimen for this group of patients.